{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:42:42Z","timestamp":1785213762818,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40291-022-00597-z","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T12:12:24Z","timestamp":1655381544000},"page":"369-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Biomarker Determinants of Early Anthracycline-Induced Left Ventricular Dysfunction in Breast Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-5267","authenticated-orcid":false,"given":"Stavroula L.","family":"Kastora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiberiu A.","family":"Pana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyo K.","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"597_CR1","unstructured":"Cancer Research UK. Breast cancer survival statistics. Published 2021. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/survival?_gl=1*1p4rtww*_ga*OTEwMDU0OTEyLjE2MzIyNTEzMDk.*_ga_58736Z2GNN*MTYzMjc1MjMyNS4yLjEuMTYzMjc1MjQxNi40NQ..&_ga=2.115066242.482372446.1632752326-910054912.1632251309. Accessed 2 Sep 2021."},{"issue":"1","key":"597_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1470-2045(17)30777-5","volume":"19","author":"B Asselain","year":"2018","unstructured":"Asselain B, Barlow W, Bartlett J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339. https:\/\/doi.org\/10.1016\/s1470-2045(17)30777-5.","journal-title":"Lancet Oncol"},{"issue":"12","key":"597_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","volume":"104","author":"P Henriksen","year":"2017","unstructured":"Henriksen P. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2017;104(12):971\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2017-312103.","journal-title":"Heart"},{"key":"597_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00342-5","author":"S Hurvitz","year":"2021","unstructured":"Hurvitz S, McAndrew N, Bardia A, et al. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021. https:\/\/doi.org\/10.1038\/s41523-021-00342-5.","journal-title":"NPJ Breast Cancer."},{"issue":"9814","key":"597_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/s0140-6736(11)61625-5","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012;379(9814):432\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(11)61625-5.","journal-title":"Lancet"},{"issue":"11","key":"597_CR6","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"S Swain","year":"2003","unstructured":"Swain S, Whaley F, Ewer M. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11):2869\u201379. https:\/\/doi.org\/10.1002\/cncr.11407.","journal-title":"Cancer"},{"issue":"22","key":"597_CR7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/circulationaha.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981\u20138. https:\/\/doi.org\/10.1161\/circulationaha.114.013777.","journal-title":"Circulation"},{"issue":"4","key":"597_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309\u201325. https:\/\/doi.org\/10.3322\/caac.21341.","journal-title":"CA Cancer J Clin"},{"key":"597_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00026","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla C. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020. https:\/\/doi.org\/10.3389\/fcvm.2020.00026.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"597_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026.","journal-title":"J Clin Epidemiol"},{"key":"597_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00035","author":"A Murabito","year":"2020","unstructured":"Murabito A, Hirsch E, Ghigo A. Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer? Front Cardiovasc Med. 2020. https:\/\/doi.org\/10.3389\/fcvm.2020.00035.","journal-title":"Front Cardiovasc Med."},{"issue":"3","key":"597_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jacbts.2018.02.003","volume":"3","author":"N Boutagy","year":"2018","unstructured":"Boutagy N, Wu J, Cai Z, et al. In vivo reactive oxygen species detection with a novel positron emission tomography tracer, 18F-DHMT, allows for early detection of anthracycline-induced cardiotoxicity in rodents. JACC Basic Transl Sci. 2018;3(3):378\u201390. https:\/\/doi.org\/10.1016\/j.jacbts.2018.02.003.","journal-title":"JACC Basic Transl Sci."},{"issue":"4","key":"597_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0006-2952(82)90162-9","volume":"31","author":"J Lown","year":"1982","unstructured":"Lown J, Chen H, Plambeck J, Acton E. Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects. Biochem Pharmacol. 1982;31(4):575\u201381. https:\/\/doi.org\/10.1016\/0006-2952(82)90162-9.","journal-title":"Biochem Pharmacol"},{"key":"597_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c140059","author":"T Tan","year":"2015","unstructured":"Tan T, Neilan T, Francis S, Plana J, Scherrer-Crosbie M. Anthracycline-induced cardiomyopathy in adults. Compr Physiol. 2015. https:\/\/doi.org\/10.1002\/cphy.c140059.","journal-title":"Compr Physiol"},{"issue":"2","key":"597_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/jci72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124(2):617\u201330. https:\/\/doi.org\/10.1172\/jci72931.","journal-title":"J Clin Invest"},{"issue":"17","key":"597_CR16","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1161\/circulationaha.115.017443","volume":"133","author":"D Li","year":"2016","unstructured":"Li D, Wang Z, Ding G, et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation. 2016;133(17):1668\u201387. https:\/\/doi.org\/10.1161\/circulationaha.115.017443.","journal-title":"Circulation"},{"key":"597_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-9589-5_9","author":"S Levi","year":"2019","unstructured":"Levi S, Cozzi A, Santambrogio P. Iron pathophysiology in neurodegeneration with brain iron accumulation. Adv Exp Med Biol. 2019. https:\/\/doi.org\/10.1007\/978-981-13-9589-5_9.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"597_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ehf2.12589","volume":"7","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu R, Mrotzek S, et al. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer: a meta-analysis. ESC Heart Fail. 2020;7(2):423\u201333. https:\/\/doi.org\/10.1002\/ehf2.12589.","journal-title":"ESC Heart Fail."},{"key":"597_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.115.002661","author":"M Bloom","year":"2016","unstructured":"Bloom M, Hamo C, Cardinale D, et al. Cancer therapy-related cardiac dysfunction and heart failure. Circ Heart Fail. 2016. https:\/\/doi.org\/10.1161\/circheartfailure.115.002661.","journal-title":"Circ Heart Fail"},{"issue":"36","key":"597_CR20","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"J Zamorano","year":"2016","unstructured":"Zamorano J, Lancellotti P, Rodriguez Mu\u00f1oz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211.","journal-title":"Eur Heart J"},{"issue":"7","key":"597_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"issue":"9","key":"597_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"key":"597_CR23","unstructured":"Cochrane Training. Chapter 24: Including non-randomized studies on intervention effects. Published 2021. https:\/\/training.cochrane.org\/handbook\/current\/chapter-24. Accessed 15 Oct 2021."},{"issue":"4","key":"597_CR24","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"C Begg","year":"1994","unstructured":"Begg C, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088. https:\/\/doi.org\/10.2307\/2533446.","journal-title":"Biometrics"},{"issue":"8","key":"597_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/btp101.","journal-title":"Bioinformatics"},{"issue":"9","key":"597_CR26","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","volume":"61","author":"M Putt","year":"2015","unstructured":"Putt M, Hahn V, Januzzi J, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015;61(9):1164\u201372. https:\/\/doi.org\/10.1373\/clinchem.2015.241232.","journal-title":"Clin Chem"},{"issue":"9","key":"597_CR27","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","volume":"107","author":"H Sawaya","year":"2011","unstructured":"Sawaya H, Sebag I, Plana J, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375\u201380. https:\/\/doi.org\/10.1016\/j.amjcard.2011.01.006.","journal-title":"Am J Cardiol"},{"issue":"8","key":"597_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.061.","journal-title":"J Am Coll Cardiol"},{"key":"597_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.014708","author":"B Demissei","year":"2020","unstructured":"Demissei B, Hubbard R, Zhang L, et al. Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc. 2020. https:\/\/doi.org\/10.1161\/jaha.119.014708.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"597_CR30","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/ejhf.1758","volume":"22","author":"J Tromp","year":"2020","unstructured":"Tromp J, Boerman L, Sama I, et al. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. Eur J Heart Fail. 2020;22(7):1239\u201346. https:\/\/doi.org\/10.1002\/ejhf.1758.","journal-title":"Eur J Heart Fail"},{"issue":"25","key":"597_CR31","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim K, Plana J, Woo A, Marwick T. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy. J Am Coll Cardiol. 2014;63(25):2751\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.073.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"597_CR32","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/circulationaha.121.054698","volume":"143","author":"S Heck","year":"2021","unstructured":"Heck S, Mecinaj A, Ree A, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. 2021;143(25):2431\u201340. https:\/\/doi.org\/10.1161\/circulationaha.121.054698.","journal-title":"Circulation"},{"issue":"3","key":"597_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/annonc\/mdw671","volume":"28","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ong G, Fazelzad R, et al. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Ann Oncol. 2017;28(3):628\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdw671.","journal-title":"Ann Oncol"},{"issue":"2","key":"597_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.14503\/thij-14-4509","volume":"42","author":"A Segura","year":"2015","unstructured":"Segura A, Radovancevic R, Demirozu Z, Frazier O, Buja L. Anthracycline treatment and ventricular remodeling in left ventricular assist device patients. Tex Heart Inst J. 2015;42(2):124\u201330. https:\/\/doi.org\/10.14503\/thij-14-4509.","journal-title":"Tex Heart Inst J"},{"key":"597_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110709","volume":"131","author":"J Pereira","year":"2020","unstructured":"Pereira J, Tosatti J, Sim\u00f5es R, Luizon M, Gomes K, Alves M. microRNAs associated to anthracycline-induced cardiotoxicity in women with breast cancer: a systematic review and pathway analysis. Biomed Pharmacother. 2020;131: 110709. https:\/\/doi.org\/10.1016\/j.biopha.2020.110709.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"597_CR36","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3390\/jcm9051418","volume":"9","author":"S Gioffr\u00e9","year":"2020","unstructured":"Gioffr\u00e9 S, Chiesa M, Cardinale D, et al. Circulating microRNAs as potential predictors of anthracycline-induced troponin elevation in breast cancer patients: diverging effects of doxorubicin and epirubicin. J Clin Med. 2020;9(5):1418. https:\/\/doi.org\/10.3390\/jcm9051418.","journal-title":"J Clin Med"},{"key":"597_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-017-0148-3","author":"S Moazeni","year":"2017","unstructured":"Moazeni S, Cadeiras M, Yang E, Deng M, Nguyen K. Anthracycline induced cardiotoxicity: biomarkers and \u201cOmics\u201d technology in the era of patient specific care. Clin Transl Med. 2017. https:\/\/doi.org\/10.1186\/s40169-017-0148-3.","journal-title":"Clin Transl Med"},{"issue":"12","key":"597_CR38","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nrc2524","volume":"8","author":"C Fischer","year":"2008","unstructured":"Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nature Rev Cancer. 2008;8(12):942\u201356. https:\/\/doi.org\/10.1038\/nrc2524.","journal-title":"Nature Rev Cancer."},{"issue":"1","key":"597_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-012-2039-z","volume":"134","author":"A Onitilo","year":"2012","unstructured":"Onitilo A, Engel J, Stankowski R, Liang H, Berg R, Doi S. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012;134(1):291\u20138. https:\/\/doi.org\/10.1007\/s10549-012-2039-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"597_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cpcardiol.2004.03.004","volume":"29","author":"S Bassuk","year":"2004","unstructured":"Bassuk S, Rifai N, Ridker P. High-sensitivity C-reactive protein. Curr Probl Cardiol. 2004;29(8):439\u201393. https:\/\/doi.org\/10.1016\/j.cpcardiol.2004.03.004.","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"597_CR41","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1016\/j.clbc.2018.03.016","volume":"18","author":"T Ng","year":"2018","unstructured":"Ng T, Phey X, Yeo H, et al. Impact of adjuvant anthracycline-based and taxane-based chemotherapy on plasma VEGF levels and cognitive function in breast cancer patients: a longitudinal study. Clin Breast Cancer. 2018;18(5):e927\u201337. https:\/\/doi.org\/10.1016\/j.clbc.2018.03.016.","journal-title":"Clin Breast Cancer"},{"issue":"21","key":"597_CR42","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1242\/dev.126.21.4895","volume":"126","author":"T Kawasaki","year":"1999","unstructured":"Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development. 1999;126(21):4895\u2013902. https:\/\/doi.org\/10.1242\/dev.126.21.4895.","journal-title":"Development"},{"issue":"5","key":"597_CR43","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/s0896-6273(00)80392-x","volume":"19","author":"T Kitsukawa","year":"1997","unstructured":"Kitsukawa T, Shimizu M, Sanbo M, et al. Neuropilin-semaphorin III\/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron. 1997;19(5):995\u20131005. https:\/\/doi.org\/10.1016\/s0896-6273(00)80392-x.","journal-title":"Neuron"},{"issue":"1","key":"597_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s1534-5807(03)00169-2","volume":"5","author":"C Gu","year":"2003","unstructured":"Gu C, Rodriguez E, Reimert D, et al. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell. 2003;5(1):45\u201357. https:\/\/doi.org\/10.1016\/s1534-5807(03)00169-2.","journal-title":"Dev Cell"},{"issue":"13","key":"597_CR45","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.molimm.2010.05.007","volume":"47","author":"V Ferreira","year":"2010","unstructured":"Ferreira V, Pangburn M, Cort\u00e9s C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol. 2010;47(13):2187\u201397. https:\/\/doi.org\/10.1016\/j.molimm.2010.05.007.","journal-title":"Mol Immunol"},{"issue":"15","key":"597_CR46","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1089\/ars.2020.8019","volume":"32","author":"V Sala","year":"2020","unstructured":"Sala V, Della Sala A, Hirsch E, Ghigo A. Signaling pathways underlying anthracycline cardiotoxicity. Antioxid Redox Signal. 2020;32(15):1098\u2013114. https:\/\/doi.org\/10.1089\/ars.2020.8019.","journal-title":"Antioxid Redox Signal"},{"issue":"8","key":"597_CR47","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/eci.12475","volume":"45","author":"P Min","year":"2015","unstructured":"Min P, Chan S. The biology of circulating microRNAs in cardiovascular disease. Eur J Clin Invest. 2015;45(8):860\u201374. https:\/\/doi.org\/10.1111\/eci.12475.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"597_CR48","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ejhf.495","volume":"18","author":"E Vegter","year":"2016","unstructured":"Vegter E, van der Meer P, de Windt L, Pinto Y, Voors A. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016;18(5):457\u201368. https:\/\/doi.org\/10.1002\/ejhf.495.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"597_CR49","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/eurheartj\/ehq013","volume":"31","author":"G Wang","year":"2010","unstructured":"Wang G, Zhu J, Zhang J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659\u201366. https:\/\/doi.org\/10.1093\/eurheartj\/ehq013.","journal-title":"Eur Heart J"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-022-00597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-022-00597-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-022-00597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T21:56:37Z","timestamp":1657662997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-022-00597-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1007\/s40291-022-00597-z","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"10 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest that are directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Ethics approval\/patient consent was not required for the present study. The study protocol was prospectively registered and accessed under the PROSPERO database (CRD42021278741).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All associated data with the present article are available as online supplementary material.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SLK: conceptualisation, methodology, critical appraisal, data collection, manuscript drafting and editing. YS: critical appraisal and data collection. TAP: critical appraisal of the manuscript and manuscript editing. PKM: supervision, critical appraisal of the manuscript and final approval of the manuscript. MAM: supervision, critical appraisal of the manuscript and final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}